Comparative Pharmacology
Head-to-head clinical analysis: OPTIRAY 240 versus OPTIRAY 320.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPTIRAY 240 versus OPTIRAY 320.
OPTIRAY 240 vs OPTIRAY 320
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OPTIRAY 240 (ioversol) is a nonionic, iodinated, water-soluble radiographic contrast agent that attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during imaging procedures. Its mechanism is physical: the iodine atoms absorb X-rays, providing radiopacity.
Iodinated radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast during radiographic procedures.
Intravenous administration: 50-150 mL of OPTIRAY 240 (iopamidol 240 mg iodine/mL) for adult computed tomography (CT) imaging, typically as a bolus or rapid infusion. Dose depends on procedure and patient size.
Intravenous administration: 50-150 mL of OPTIRAY 320 (ioversol 320 mg iodine/mL) per injection for contrast-enhanced CT; total dose not to exceed 250 mL. Intra-arterial: variable per procedure.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe impairment).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (creatinine clearance >60 mL/min). Prolonged in renal impairment; may exceed 20 hours in severe renal failure (CrCl <30 mL/min).
Primarily renal (glomerular filtration); >90% of administered dose excreted unchanged in urine within 24 hours; <1% biliary/fecal.
Renal excretion of unchanged drug via glomerular filtration; approximately 95% eliminated in urine within 24 hours. Less than 1% excreted in feces via biliary route.
Category C
Category C
Radiological Contrast Agent
Radiological Contrast Agent